The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $500 million SEC-registered offering of 6,849,316 shares of common stock by Intra-Cellular Therapies, Inc. The common stock is listed on the Nasdaq Global Select Market under the symbol “ITCI.”

Intra-Cellular is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system.

The Davis Polk capital markets team included partners Michael Kaplan and Stephen A. Byeff and associates Sarah Greene and Fei Deng. Counsel Marcie A. Goldstein provided FINRA advice. The tax team included partner Michael Mollerus and associate Dmitry Dobrovolskiy. The intellectual property team included partner David R. Bauer and associates Adrian Rabin and Ben Malone. All members of the Davis Polk deal team are based in the New York office.